Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 230 PARK AVENUE, SUITE 3350 NEW YORK NY 10169 |
Tel: | N/A |
Website: | https://www.ymabs.com |
IR: | See website |
Key People | ||
Michael Rossi President, Chief Executive Officer, Director | Thomas Gad Vice Chairman of the Board, Chief Business Officer | Bo Kruse Chief Financial Officer, Executive Vice President, Treasurer, Secretary |
Joris Wiel Jan Wilms Chief Operating Officer, Senior Vice President | Torben Lund-Hansen Senior Vice President, Chief Technical Officer | Steen Lisby Senior Vice President, Chief Scientific Officer |
Vignesh Rajah Senior Vice President, Chief Medical Officer | Susan Smith Senior Vice President, Chief Commercial Officer |
Business Overview |
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types. |
Financial Overview |
For the fiscal year ended 31 December 2023, Y-mAbs Therapeutics Inc revenues increased 30% to $84.8M. Net loss decreased 78% to $21.4M. Revenues reflect License revenue increase of 71% to $84.3M. Lower net loss reflects Therapeutic products segment loss decrease of 73% to $25.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.19 to -$0.49. |
Employees: | 100 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $590.71M as of Dec 31, 2023 |
Annual revenue (TTM): | $84.82M as of Dec 31, 2023 |
EBITDA (TTM): | -$20.46M as of Dec 31, 2023 |
Net annual income (TTM): | -$21.43M as of Dec 31, 2023 |
Free cash flow (TTM): | -$27.23M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 43,777,105 as of Feb 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |